综上所述,zanubrutinib在治疗初治CLL/SLL患者方面展现了显著的优势,不仅提高了临床疗效,还大幅提升了患者的生活质量。 In summary, zanubrutinib has demonstrated sustained superiority over the traditional BR regimen in treating treatment-naive CLL/SLL patients, as evidenced by the 5-year follow-up data ...
with the keynote-177 with pembrolizumab we have 35 patients without progression of the disease after five years of follow-up. clearly, the goal is to hopefully cure metastatic disease. this is the first time it is poss...
171 pts in the NIVO + IPI arm and 84 pts in the chemo arm had centrally confirmed MSI-H/dMMR result by either immunohistochemistry and/or polymerase chain reaction-based tests. With 24.3 months of median follow-up, N...
PFS-2, defined as time from randomization to progression on second line therapy, is potentially a more reliable surrogate than PFS but requires additional follow-up time. We evaluated the validity and efficiency of PFS-2 as a surrogate endpoint for OS and compared its performance with PFS....
Rapid build up of the device current can occur in event of inductor saturation or when the input and output voltages are equal (non or very short inductor reset time). The SOA mode is triggered whenever the device reaches current limit (IOCP) and the on-time is less than tSOA. ...
pfs is a provider of software and technology solutions for financial services businesses across the entire value chain of lending activity, covering processes from origination to collection. pfs also has a number of data efficiency solutions deployed within banks to optimise credit risk. pfs was found...
At data cutoff December 6, 2019, the median follow-up time was 9.3, 8.8, and 9.1 months in arms A, B, and C, respectively, for patients with stage IIIB disease, and 8.3, 8.6, and 7.7 months for those with stage IV disease, respectively.1 Analysis was reported for the secondary end...
The time to next treatment (TTNT) or death was also evaluated. At a median follow-up of 20.0 months, the experimental arm demonstrated a median TTNT of 24.0 months (95% CI, 17.8-29.7) vs 10.9 months (95% CI, 8.7-12.5) in the control arm at a median follow-up of 20.2 months. Pir...
构建生存曲线图的第一步是理解数据集结构。以R语言中的survival和survminer包为例，数据集通常包含研究机构代码（inst）、生存时间（time，以天、周、月为单位）和删失状态（status，1表示删失，0表示死亡）等关键变量。性别（sex）虽然未在示例图中直接提及，但在肿瘤试验中，它作为分组信息，帮助展示不...
The findings are being presented for the first time today at 10:45 a.m. ET during a late-breaking abstract proffered paper session at the European Society for Medical Oncology (ESMO) Congress 2023 (abstract #LBA38). ...